Q2 2024 Earnings Estimate for Amedisys, Inc. (NASDAQ:AMED) Issued By William Blair

Amedisys, Inc. (NASDAQ:AMED) – Equities researchers at William Blair upped their Q2 2024 earnings per share (EPS) estimates for shares of Amedisys in a research note issued to investors on Thursday, April 25th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings of $1.18 per share for the quarter, up from their previous forecast of $1.04. The consensus estimate for Amedisys’ current full-year earnings is $4.54 per share. William Blair also issued estimates for Amedisys’ Q3 2024 earnings at $1.12 EPS and Q4 2024 earnings at $1.21 EPS.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The business had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. During the same quarter in the previous year, the firm earned $1.00 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year.

AMED has been the topic of several other research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price target on shares of Amedisys in a report on Thursday. Royal Bank of Canada lifted their price target on Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 25th. StockNews.com downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Raymond James reissued a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $97.50.

Amedisys Stock Up 0.7 %

NASDAQ AMED opened at $91.79 on Friday. Amedisys has a 52 week low of $73.10 and a 52 week high of $96.44. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. The business’s fifty day simple moving average is $92.54 and its 200-day simple moving average is $93.35. The firm has a market cap of $3.00 billion, a PE ratio of -143.42, a P/E/G ratio of 4.28 and a beta of 0.86.

Institutional Trading of Amedisys

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Pentwater Capital Management LP grew its position in Amedisys by 239.5% in the 3rd quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider’s stock valued at $106,850,000 after acquiring an additional 807,000 shares in the last quarter. Westchester Capital Management LLC grew its position in Amedisys by 269.7% in the 3rd quarter. Westchester Capital Management LLC now owns 850,386 shares of the health services provider’s stock valued at $79,426,000 after acquiring an additional 620,386 shares in the last quarter. Water Island Capital LLC grew its position in Amedisys by 185.0% in the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after acquiring an additional 461,368 shares in the last quarter. Norges Bank acquired a new position in Amedisys in the 4th quarter valued at about $34,032,000. Finally, Segantii Capital Management Ltd acquired a new position in Amedisys in the 4th quarter valued at about $32,776,000. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.